Author

Nicky Holland

Institution: Ashford and St Peter's Hospitals NHS Foundation Trust

Observed institutions: University Hospitals Birmingham NHS Foundation Trust, Public Health England, National Institute for Health and Care Research, University of Oxford, Public Health Scotland, Renewable Energy Alaska Project, National Records of Scotland, Nepal Health Research Council, Ashford and St Peter's Hospitals NHS Foundation Trust, Oxford University Clinical Research Unit, Intensive Care National Audit & Research Centre, Oxford University Clinical Research Unit Indonesia, Canadian Critical Care Trials Group

ORCID: 0000-0001-5553-1958

Observed ORCID: 0000-0001-5553-1958

OpenAlex ID: A5020404470

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 566

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 512

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 402

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 361

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 303

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

2021 · Hesham Abdelhady, Marwa Abdelrazik, et al. · JAMA · 215

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 146

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

2022 · Simin Florescu, Delia Stanciu, et al. · JAMA · 143

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 141

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial

2021 · Yaseen M. Arabi, Anthony C. Gordon, et al. · Intensive Care Medicine · 102

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial

2023 · Simin Florescu, Delia Stanciu, et al. · JAMA · 68

Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials

2023 · The LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Simin Florescu, et al. · JAMA · 59

Feasibility and acceptability of a novel forehead-mounted wireless heart rate monitoring device in preterm infants: a prospective multicenter observational cohort study

2026 · Vennila Ponnusamy, Nicky Holland, et al. · The Journal of Maternal-Fetal & Neonatal Medicine · 1

Feasibility and acceptability of a novel forehead-mounted wireless heart rate monitoring device in preterm infants: a prospective multicenter observational cohort study

2026 · Vennila Ponnusamy, Nicky Holland, et al. · Figshare

Works count: 14

Citation count: 3,019

H-index: 12

I10-index: 12